News - Medicago and The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, reported positive interim results from a Phase I clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").
News - Aeterna Zentaris announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide® product. The principal effect of such agreements is to transfer manufacturing rights and to grant a manufacturing license for Cetrotide® to a subsidiary of Merck KGaA of Darmstadt, Germany ("Merck Serono"), in all jurisdictions.
News - Aeterna Zentaris announced that David A. Dodd has been appointed President and Chief Executive Officer of the Company, succeeding Juergen Engel, PhD. Mr. Dodd has also been appointed director on the Company's Board of Directors. Aeterna Zentaris Inc. is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs.
News - Aeterna Zentaris announces the signing of a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. for AEZS-108 in endometrial cancer. Ergomed was selected as the contract clinical development organization to conduct the multicenter, multinational, randomized Phase 3 trial with AEZS-108 in endometrial cancer.
News - Aeterna Zentaris presented encouraging updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models. Results further showed the compounds' high potential for the treatment of luteinizing hormone-releasing hormone ("LHRH") receptor positive tumors. Data were presented earlier today by Babette Aicher, PhD, the Company's Director of Preclinical Development, during a poster presentation at the American Association for Cancer Research ("AACR") annual meeting currently being held in Washington D.C.
News - Medicago Inc. (TSX: MDG); (OTCQX: MDCGF), société biopharmaceutique spécialisée dans la mise au point de vaccins très efficaces et concurrentiels, fondés sur des technologies de fabrication exclusives et sur des particules pseudo-virales (PPV), et L'Institut de recherche sur les maladies infectieuses (IDRI), organisme de recherche sans but lucratif établi à Seattle et chef de file dans la mise au point d'adjuvants utilisés dans des vaccins contre des maladies infectieuses, ont annoncé aujourd'hui qu'ils présenteront les résultats provisoires positifs de l'essai clinique de phase I mené sur le vaccin candidat à PPV contre la grippe aviaire H5N1 (« vaccin H5N1 ») au World Vaccine Congress. Le congrès aura lieu du 16 au 18 avril 2013, au Gaylord National Hotel and Convention Center, à Washington, D.C.
News - For over 20 years now, Professor Simard has been working on genetic susceptibility to breast cancer. These latest research findings helped identify 49 new genetic variations involved in the risk of developing this disease, almost tripling the number of variations now known. In the vast majority of breast cancer cases affecting the general population, it is the interaction between these genetic variations and other environmental and lifestyle factors that is involved in the development of the disease.
News - This focused partnering event will showcase cutting edge cancer R&D activities in six regions and clusters. Massachusetts, Quebec, Toulouse, Oslo, the UK "Golden triangle" and the Chicago Cancer Cluster have teamed up to present their innovative oncology pipelines to an international audience as a satellite event to BIO 2013. The compact event features company and poster presentations and focused networking opportunities with an international oncology community.
News - DiagnoCure is pleased to report that Dr. Harry Rittenhouse spoke about the clinical utility of the urinary marker PCA3 during the International Conference on Prostate Cancer Prevention 2013 with Consensus Conference on Chemoprevention of Prostate Cancer held during the 28th annual European Association of Urology congress held in Milan from March 15-19th.
News - This morning, the Canadian Cancer Society (CCS) announced that it will grant $2.3 million to researchers in Montreal and Quebec City who are aiming to develop cancer vaccines. This includes Dr Yves Fradet’s team at Université Laval aims to apply this approach to bladder cancer. In 2012, this disease affected 7,800 people in Canada and 2,740 people in Quebec.